Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Summary

• Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 11 shares of common stock on June 17, 2024.
• The shares were acquired at a price of $885.01 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Sulzberger's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a neutral to slightly positive sentiment as it shows a director's continued investment in the company.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to insider transactions and is common for directors of publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as required by the Securities and Exchange Commission (SEC).
• Directors and officers of companies like Eli Lilly are required to disclose their transactions in company stock.
• Similar filings are made by directors of other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) when they acquire or dispose of company stock.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows a director's continued investment in the company.

Key Dates

Keywords

Form 4, insider trading, stock acquisition, director, share deferral, Eli Lilly, LLY